Advancements and Applications of Antibody Drug Conjugates in HER2-Negative Breast Cancer

Patients with triple negative and HR-positive/HER2-negative breast cancer have limited treatment options after the development of endocrine resistance. This dearth of options is particularly acute for Black women and other marginalized patients, and results in treatment disparities. Antibody-drug conjugates (ADCs) are novel agents, which may improve outcomes for patients. However, clinicians lack the ability to implement them into practice appropriately or may be hesitant to use them altogether.

In this Grand Rounds activity, a breast cancer expert will guide participants through a discussion of criteria to select patients to receive ADCs, adverse event (AE) management, and strategies to foster equitable care of patients with metastatic breast cancer (mBC).

At the conclusion of this activity, learners will be able to better:

• Evaluate unmet needs in the management of HER2- mBC, including expanding treatment options for those who have progressive disease and the implementation of policies to promote equitable care
• Select patients with HER2- mBC, who have progressed despite prior treatment, to receive ADC-based regimens based on guidelines, expert consensus, and latest clinical trial findings
• Integrate strategies to monitor for and manage AEs in patients receiving ADCs for HER2- mBC

This program has been supported by an independent educational grant from Gilead Sciences, Inc.

Community oncologists and their interprofessional team of pharmacists, nurses, nurse practitioners (NPs), and physician associates (PAs)

It is the policy of CE Concepts, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CE Concepts, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. Relevant financial relationships exist between the following individuals and commercial interests:

Dr. Abdou reports the following financial relationships:

Consultant: AstraZeneca; Exact Sciences Corporation (uncompensated); and Pfizer Inc.

Research: Carisma Therapeutics Inc.

The following individuals have no financial relationships to disclose:

Alaa Bawaneh, MD, PhD (Peer Reviewer)
Albert Eubanks, Jr., RN (Peer Reviewer)
Mary Gleason, PhD, CHCP (Planning Committee)
David Modrak, PhD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CE Concepts, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.